Compounding vs Manufacturing: Why Compounded GLP-1 Costs Less
Same molecule. Same results. Fraction of the price. Here is why compounded GLP-1 medications are dramatically cheaper -- and just as effective.
When patients learn they can get compounded semaglutide for $99/month instead of $1,350/month for brand-name Wegovy, the first question is always: "What is the catch?" The answer: there is no catch. The medication is the same. The difference is the business model behind it.
Side-by-Side Comparison
Brand vs Compounded
| Factor | Brand-Name (Wegovy) | Compounded (Trimi) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Monthly cost | $1,350 | $99 |
| Manufacturer | Novo Nordisk | FDA-registered 503A community sterile-compounding pharmacy |
| Quality testing | Internal QC | Third-party COA |
| FDA oversight | Full NDA approval | 503A registration + inspection |
| Delivery | Pre-filled pen | Vial with syringes |
| Insurance needed | Usually yes | No |
Why Compounding Costs 90% Less
Cost Drivers Compounders Avoid
- No R&D recoupment: $0 spent on discovery and clinical trials (vs $1-3 billion for Novo Nordisk)
- No marketing spend: $0 on TV ads, sales reps, celebrity endorsements (vs hundreds of millions)
- No patent premium: Pricing based on production cost, not monopoly pricing
- No fancy packaging: Vials instead of expensive autoinjector pen devices
- No shareholder pressure: No need to maximize profit margins for Wall Street
- Direct-to-patient: No wholesaler, distributor, or pharmacy middleman margins
Quality and Safety Standards
FDA-registered 503A outsourcing facilities are legally required to follow current Good Manufacturing Practices (cGMP), submit to FDA inspections, report adverse events to the FDA, use USP-grade ingredients, test each batch for potency, sterility, and endotoxins, and maintain detailed production records. Trimi additionally requires third-party certificates of analysis for every batch and works only with pharmacies that have clean FDA inspection histories.
The Legal Basis
The FDA Drug Shortage List authorizes 503A community sterile-compounding pharmacy to compound copies of listed drugs. Both semaglutide and tirzepatide have been on the shortage list due to unprecedented demand exceeding supply. This is the same legal framework that allows compounding of many other medications -- it is established, regulated, and widely used throughout medicine.
Same Molecule. $99/Month.
Quality compounded semaglutide from FDA-registered pharmacies. Tirzepatide $125/month. No insurance needed.
Get StartedMedical Disclaimer
This article is for informational purposes. Compounding regulations can change. Verify pharmacy credentials. Compounded medications are not FDA-approved products but contain FDA-approved active ingredients. Consult your healthcare provider.
More on GLP-1 cost
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).